Crescent Biopharma, Inc. in brief
Crescent Biopharma, Inc. is a listed company in the Biotechnology industry, based in Maryland, USA. It was founded in 2003. Its last known market value was $195 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $11 M and a net loss of $154 M. It employs about 44 people. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol CBIO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Crescent Biopharma, Inc.
We were incorporated under the laws of the State of Delaware in 2003. Our company, formerly known as GlycoMimetics, Inc., is a biotechnology company that is the result of a reverse recapitalization transaction with a private company named Crescent Biopharma, Inc.. Prior to the reverse recapitalization transaction, Pre-Merger Crescent was established and incorporated under the laws of the state of Delaware on September 19, 2024. On June 16, 2025, in connection with the reverse recapitalization transaction with Pre-Merger Crescent, we changed our jurisdiction of incorporation from the state of Delaware to the Cayman Islands pursuant to a plan of conversion.
Crescent Biopharma, Inc. timeline
- 2003
- 🏁· approximateFounded
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- 🔔· approximateInitial public offering on Nasdaq
- 2025
- 💰Record revenue of $11 millionFY2025, the highest of the 5 years on record.
- 💰Record net income of $0 millionFY2025, the highest profit of the 3 years on record.
- ✎Renamed Crescent Biopharma, Inc.Formerly Glycomimetics Inc.
Events of Crescent Biopharma, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,149 (Jan 2020) · #3,319 (Jan 2021) · #4,662 (Jan 2022) · #4,130 (Dec 2022) · #4,181 (Jul 2023) · #3,268 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -1420.1%
- Operating margin
- -1408.0%
- Return on equity
- -75.8%
- Liabilities / assets
- 15.5%
- Revenue growth
- +108300.0%
- R&D / revenue
- 1273.9%
- Revenue per employee
- $246 K
- Profit per employee
- $-3.5 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $11M | — | $-153M | $-154M | -1420.1% |
| Dec 2024 | — | — | $-40M | $-38M | — |
| Dec 2023 | $0M | -87.5% | $-39M | $-37M | -369000.0% |
| Dec 2022 | $0M | -93.1% | $-47M | $-47M | -58362.5% |
| Dec 2021 | $1M | -88.6% | $-63M | $-63M | -5468.1% |
| Dec 2020 | $10M | — | $-52M | $-51M | -502.3% |
| Dec 2019 | — | — | $-61M | $-58M | — |
| Dec 2018 | — | — | $-52M | $-48M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-72M | $1M | $-72M | — | — |
| Dec 2024 | $-31M | $0M | $-31M | $-0.59 | — |
| Dec 2023 | $-35M | $0M | $-35M | $-0.58 | — |
| Dec 2022 | $-46M | $0M | $-47M | $-0.89 | — |
| Dec 2021 | $-57M | $0M | $-58M | $-1.23 | — |
| Dec 2020 | $-39M | $0M | $-39M | $-1.12 | — |
| Dec 2019 | $-52M | $0M | $-52M | $-1.34 | — |
| Dec 2018 | $-43M | $0M | $-43M | $-1.18 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $3M, net income $-38M. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 15, 20268-KCurrent reportOther events
- Jul 30, 202610-QQuarterly report · period to Jun 2026
- Jul 30, 20268-KCurrent reportResults of operations
- Jul 15, 20268-KCurrent reportOther events
- Jul 14, 20268-KCurrent reportResults of operations
- Jun 22, 202610-Q/AQuarterly report (amended) · period to Mar 2026
- Jun 3, 20268-KCurrent reportShareholder vote
- Apr 29, 20268-KCurrent reportResults of operations
- Apr 29, 202610-QQuarterly report · period to Mar 2026
- Apr 21, 2026DEF 14AProxy statement
Official filings of Crescent Biopharma, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $11 M
- Operating income
- $-153 M
- Net income
- $-154 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $240 M
- Total liabilities
- $37 M
- Total equity
- $203 M
As of December-2025
Top 100 institutional investors in Crescent Biopharma, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 5,904,998 | +1,771,484 (+42.86%) | 15.18% | $86 M | Nov 10, 2026 |
| 2 | Fairmount Funds Management LLC | 3,601,316 | +853,450 (+31.06%) | 9.26% | $53 M | Nov 16, 2026 |
| 3 | BVF Inc/il | 3,093,590 | +344,827 (+12.54%) | 7.95% | $45 M | Nov 16, 2026 |
| 4 | Vestal Point Capital, LP | 3,000,000 | +1,370,000 (+84.05%) | 7.71% | $44 M | Nov 16, 2026 |
| 5 | BlackRock, Inc. | 2,138,232 | +866,470 (+68.13%) | 5.50% | $31 M | Nov 13, 2026 |
| 6 | Venrock Adviser, LLC | 2,133,734 | +158 (+0.01%) | 5.49% | $31 M | Nov 16, 2026 |
| 7 | Fcpm III Services B.V. | 2,022,679 | +344,827 (+20.55%) | 5.20% | $30 M | Nov 16, 2026 |
| 8 | Opaleye Management Inc. | 1,645,984 | +326,633 (+24.76%) | 4.23% | $24 M | Nov 16, 2026 |
| 9 | Balyasny Asset Management L.P. | 1,611,958 | -50,959 (-3.06%) | 4.14% | $24 M | Nov 16, 2026 |
| 10 | Vanguard Capital Management LLC | 1,268,637 | +500,882 (+65.24%) | 3.26% | $19 M | Nov 13, 2026 |
| 11 | Tang Capital Management LLC | 1,160,000 | 0 (0.00%) | 2.98% | $17 M | Nov 16, 2026 |
| 12 | Jennison Associates LLC | 1,102,081 | +723,574 (+191.17%) | 2.83% | $16 M | Nov 16, 2026 |
| 13 | Blackstone Inc. | 1,060,281 | +997,634 (+1592.47%) | 2.73% | $15 M | Nov 16, 2026 |
| 14 | Logos Global Management LP | 850,000 | -1,050,000 (-55.26%) | 2.19% | $12 M | Nov 16, 2026 |
| 15 | State Street Corp | 843,070 | +527,483 (+167.14%) | 2.17% | $12 M | Nov 12, 2026 |
| 16 | Geode Capital Management, LLC | 735,089 | +350,513 (+91.14%) | 1.89% | $11 M | Nov 6, 2026 |
| 17 | Perceptive Advisors LLC | 706,942 | +500,000 (+241.61%) | 1.82% | $10 M | Nov 16, 2026 |
| 18 | Ameriprise Financial Inc | 680,736 | +378,168 (+124.99%) | 1.75% | $10 M | Nov 16, 2026 |
| 19 | Adage Capital Partners GP, L.L.C. | 500,000 | New | 1.29% | $7 M | Nov 16, 2026 |
| 20 | Siren, L.L.C. | 400,000 | New | 1.03% | $6 M | Nov 12, 2026 |
| 21 | RTW Investments, LP | 372,856 | 0 (0.00%) | 0.96% | $5 M | Nov 16, 2026 |
| 22 | NEXTBio Capital Management LP | 372,856 | 0 (0.00%) | 0.96% | $5 M | Nov 13, 2026 |
| 23 | Remedium Capital Partners, LLC | 361,250 | 0 (0.00%) | 0.93% | $5 M | Nov 13, 2026 |
| 24 | Squadron Capital Management LLC | 350,000 | New | 0.90% | $5 M | Nov 16, 2026 |
| 25 | Citadel Advisors LLC | 349,656 | New | 0.90% | $5 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vanguard Portfolio Management LLC | 287,397 | +98,594 (+52.22%) | 0.74% | $4 M | Nov 13, 2026 |
| 27 | Sphera Funds Management LTD. | 279,718 | New | 0.72% | $4 M | Nov 16, 2026 |
| 28 | Woodline Partners LP | 269,535 | +175,047 (+185.26%) | 0.69% | $4 M | Nov 16, 2026 |
| 29 | ADAR1 Capital Management, LLC | 231,328 | +213,053 (+1165.82%) | 0.59% | $3 M | Nov 16, 2026 |
| 30 | Northern Trust Corp | 230,395 | +91,617 (+66.02%) | 0.59% | $3 M | Nov 16, 2026 |
| 31 | Goldman Sachs Group Inc | 227,258 | New | 0.58% | $3 M | Nov 16, 2026 |
| 32 | Two Sigma Investments, LP | 211,284 | +24,410 (+13.06%) | 0.54% | $3 M | Nov 16, 2026 |
| 33 | Vanguard Fiduciary Trust Co | 208,839 | +133,614 (+177.62%) | 0.54% | $3 M | Nov 13, 2026 |
| 34 | UBS Group AG | 205,794 | +30,612 (+17.47%) | 0.53% | $3 M | Nov 10, 2026 |
| 35 | Sectoral Asset Management Inc | 167,600 | +46,300 (+38.17%) | 0.43% | $2 M | Nov 13, 2026 |
| 36 | Ikarian Capital, LLC | 150,061 | New | 0.39% | $2 M | Nov 16, 2026 |
| 37 | Nuveen, LLC | 144,663 | +97,034 (+203.73%) | 0.37% | $2 M | Nov 10, 2026 |
| 38 | Marshall Wace, LLP | 131,409 | -82,891 (-38.68%) | 0.34% | $2 M | Nov 13, 2026 |
| 39 | Seven Grand Managers, LLC | 100,000 | New | 0.26% | $1 M | Nov 16, 2026 |
| 40 | Charles Schwab Investment Management Inc | 93,663 | +43,405 (+86.36%) | 0.24% | $1 M | Nov 16, 2026 |
| 41 | Bank Of America Corp /de/ | 90,646 | +64,825 (+251.06%) | 0.23% | $1 M | Nov 16, 2026 |
| 42 | Millennium Management LLC | 84,896 | -318,963 (-78.98%) | 0.22% | $1 M | Nov 16, 2026 |
| 43 | XTX Topco Ltd | 80,064 | +69,500 (+657.89%) | 0.21% | $1 M | Nov 16, 2026 |
| 44 | Algert Global LLC | 75,957 | New | 0.20% | $1 M | Nov 17, 2026 |
| 45 | Burkehill Global Management, LP | 74,000 | 0 (0.00%) | 0.19% | $1 M | Nov 16, 2026 |
| 46 | Wellington Management Group LLP | 73,086 | +58,486 (+400.59%) | 0.19% | $1 M | Nov 16, 2026 |
| 47 | Bank of New York Mellon Corp | 67,826 | +22,048 (+48.16%) | 0.17% | $1 M | Nov 5, 2026 |
| 48 | Susquehanna International Group, LLP | 55,725 | New | 0.14% | $1 M | Nov 16, 2026 |
| 49 | Boothbay Fund Management, LLC | 42,794 | New | 0.11% | $1 M | Nov 16, 2026 |
| 50 | Quadrature Capital Ltd | 41,175 | New | 0.11% | $1 M | Nov 13, 2026 |
| 51 | Schonfeld Strategic Advisors LLC | 32,349 | New | 0.08% | $0 M | Nov 16, 2026 |
| 52 | Price T Rowe Associates Inc /MD/ | 32,326 | -243,255 (-88.27%) | 0.08% | $0 M | Nov 16, 2026 |
| 53 | Rhumbline Advisers | 31,145 | +5,658 (+22.20%) | 0.08% | $0 M | Nov 10, 2026 |
| 54 | Engineers Gate Manager LP | 28,640 | New | 0.07% | $0 M | Nov 16, 2026 |
| 55 | Man Group plc | 26,760 | New | 0.07% | $0 M | Nov 16, 2026 |
| 56 | Vanguard Global Advisers, LLC | 25,171 | +22,457 (+827.45%) | 0.06% | $0 M | Nov 13, 2026 |
| 57 | Moore Capital Management, LP | 25,000 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 58 | Persistent Asset Partners Ltd | 24,932 | +13,964 (+127.32%) | 0.06% | $0 M | Nov 13, 2026 |
| 59 | Morgan Stanley | 22,492 | +4,794 (+27.09%) | 0.06% | $0 M | Nov 13, 2026 |
| 60 | Prudential Financial Inc | 21,032 | New | 0.05% | $0 M | Nov 16, 2026 |
| 61 | Quantinno Capital Management LP | 20,983 | New | 0.05% | $0 M | Nov 13, 2026 |
| 62 | Soros Fund Management LLC | 20,000 | New | 0.05% | $0 M | Nov 13, 2026 |
| 63 | Corient Private Wealth LP | 19,610 | New | 0.05% | $0 M | Nov 16, 2026 |
| 64 | Virtus Investment Advisers, LLC | 17,708 | -550 (-3.01%) | 0.05% | $0 M | Nov 12, 2026 |
| 65 | Barclays PLC | 17,625 | +13,163 (+295.00%) | 0.05% | $0 M | Nov 6, 2026 |
| 66 | BNP Paribas Financial Markets | 17,015 | +13,712 (+415.14%) | 0.04% | $0 M | Nov 12, 2026 |
| 67 | MetLife Investment Management, LLC | 16,655 | +3,875 (+30.32%) | 0.04% | $0 M | Nov 16, 2026 |
| 68 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 15,038 | +5,137 (+51.88%) | 0.04% | $0 M | Nov 16, 2026 |
| 69 | Rafferty Asset Management, LLC | 14,435 | New | 0.04% | $0 M | Nov 13, 2026 |
| 70 | Jpmorgan Chase & Co | 14,308 | +5,288 (+58.63%) | 0.04% | $0 M | Nov 12, 2026 |
| 71 | Creative Planning | 11,676 | New | 0.03% | $0 M | Nov 2, 2026 |
| 72 | Invesco Ltd. | 11,542 | -189 (-1.61%) | 0.03% | $0 M | Nov 12, 2026 |
| 73 | ACT Capital Partners, L.P. | 11,500 | — | 0.03% | $0 M | Nov 6, 2026 |
| 74 | Wells Fargo & Company/mn | 8,841 | -10,859 (-55.12%) | 0.02% | $0 M | Nov 16, 2026 |
| 75 | Police & Firemen's Retirement System of New Jersey | 8,464 | +2,095 (+32.89%) | 0.02% | $0 M | Nov 9, 2026 |
| 76 | New York State Common Retirement Fund | 7,600 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 77 | Citigroup Inc | 6,865 | -3,276 (-32.30%) | 0.02% | $0 M | Nov 4, 2026 |
| 78 | Simplex Trading, LLC | 3,413 | New | 0.01% | $0 M | Nov 4, 2026 |
| 79 | Legal & General Group Plc | 2,750 | +653 (+31.14%) | 0.01% | $0 M | Nov 16, 2026 |
| 80 | Rockefeller Capital Management L.P. | 1,857 | New | 0.00% | $0 M | Nov 13, 2026 |
| 81 | Royal Bank Of Canada | 1,499 | +818 (+120.12%) | 0.00% | $0 M | Nov 16, 2026 |
| 82 | Employees Retirement System of Texas | 1,486 | New | 0.00% | $0 M | Nov 10, 2026 |
| 83 | Tower Research Capital LLC (TRC) | 1,342 | -419 (-23.79%) | 0.00% | $0 M | Nov 16, 2026 |
| 84 | Sterling Capital Management LLC | 960 | +884 (+1163.16%) | 0.00% | $0 M | Oct 22, 2026 |
| 85 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 848 | New | 0.00% | $0 M | Nov 16, 2026 |
| 86 | California State Teachers Retirement System | 297 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 87 | Parallel Advisors, LLC | 231 | -33 (-12.50%) | 0.00% | $0 M | Nov 3, 2026 |
| 88 | Farther Finance Advisors, LLC | 215 | New | 0.00% | $0 M | Oct 8, 2026 |
| 89 | Allworth Financial LP | 202 | +41 (+25.47%) | 0.00% | $0 M | Nov 17, 2026 |
| 90 | GAMMA Investing LLC | 148 | New | 0.00% | $0 M | Oct 8, 2026 |
| 91 | Caitong International Asset Management Co., Ltd | 103 | +82 (+390.48%) | 0.00% | $0 M | Oct 29, 2026 |
| 92 | SBI Securities Co., Ltd. | 71 | +3 (+4.41%) | 0.00% | $0 M | Oct 22, 2026 |
| 93 | Signaturefd, LLC | 67 | New | 0.00% | $0 M | Oct 23, 2026 |
| 94 | Arax Advisory Partners | 56 | New | 0.00% | $0 M | Nov 12, 2026 |
| 95 | Russell Investments Group, Ltd. | 40 | -1,686 (-97.68%) | 0.00% | $0 M | Nov 6, 2026 |
| 96 | Fortitude Family Office, LLC | 40 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 97 | Global Retirement Partners, LLC | 29 | New | 0.00% | $0 M | Nov 10, 2026 |
| 98 | Osaic Holdings, Inc. | 26 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 99 | Root Financial Partners, LLC | 26 | New | 0.00% | $0 M | Oct 21, 2026 |
| 100 | EverSource Wealth Advisors, LLC | 23 | New | 0.00% | $0 M | Nov 4, 2026 |
Superinvestors holding Crescent Biopharma, Inc.
1 of the well-known investors value.today follows, from their newest Form 13F.
- Soros Fund Management · Soros Fund Management$0 Mnew · Sep 30, 2026
Mutual funds holding Crescent Biopharma, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 661,946 | $12 M | 1.7% | <0.01% | −5.3% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 516,613 | $9 M | 1.3% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 432,286 | $6 M | 1.1% | 0.07% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC | 292,679 | $6 M | 0.75% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 356,090 | $5 M | 0.92% | 0.23% | +42% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 199,418 | $4 M | 0.51% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 236,413 | $3 M | 0.61% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 187,920 | $3 M | 0.48% | 0.03% | −15% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 221,488 | $3 M | 0.57% | 0.07% | new | Jul 31, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 113,421 | $2 M | 0.29% | 0.04% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC | 149,413 | $2 M | 0.38% | 0.07% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC | 103,161 | $2 M | 0.27% | <0.01% | −1.3% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 83,801 | $2 M | 0.22% | <0.01% | +2.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC | 69,195 | $1 M | 0.18% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 71,187 | $1 M | 0.18% | 0.08% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC | 65,700 | $1 M | 0.17% | 0.07% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 38,989 | $1 M | 0.10% | <0.01% | −2.6% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 52,768 | $1 M | 0.14% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 39,685 | $1 M | 0.10% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 28,660 | $0 M | 0.07% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 22,637 | $0 M | 0.06% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 20,234 | $0 M | 0.05% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 17,565 | $0 M | 0.05% | <0.01% | +47% | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 15,612 | $0 M | 0.04% | 0.01% | +291% | May 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 17,631 | $0 M | 0.05% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 15,700 | $0 M | 0.04% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 18,969 | $0 M | 0.05% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 12,699 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 11,053 | $0 M | 0.03% | <0.01% | +10% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 11,212 | $0 M | 0.03% | <0.01% | −11% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 10,796 | $0 M | 0.03% | <0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 10,253 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 8,300 | $0 M | 0.02% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 10,277 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 7,600 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 7,246 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 7,084 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 6,023 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 5,959 | $0 M | 0.02% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 5,460 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 4,778 | $0 M | 0.01% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,633 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 4,483 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 4,414 | $0 M | 0.01% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 3,396 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 3,294 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 3,209 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 3,763 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 2,837 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 2,659 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,400 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 2,400 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 2,741 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 2,529 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 2,503 | $0 M | <0.01% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 1,960 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 1,944 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 1,726 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,907 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 1,525 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 1,862 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 974 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 751 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 907 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 545 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 454 | $0 M | <0.01% | <0.01% | +64% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 200 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 120 | $0 M | <0.01% | <0.01% | +5.3% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 68 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Crescent Biopharma, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Joshua T. BrummChief Executive Officer, Director | Sell10b5-1 plan | -7,837 | $16.71 | $131 K | 271,765 | Form 4 |
| filed | Jonathan McNeillPresident and COO | Sell10b5-1 plan | -3,839 | $16.71 | $64 K | 134,588 | Form 4 |
| filed | Richard William ScalzoChief Financial Officer | Sell10b5-1 plan | -568 | $17.90 | $10 K | 19,730 | Form 4 |
| filed | Ryan LynchSee Remarks | Sell10b5-1 plan | -240 | $17.90 | $4 K | 13,631 | Form 4 |
| filed | Jan PinkasChief Scientific Officer | Sell10b5-1 plan | -658 | $17.90 | $12 K | 21,581 | Form 4 |
| filed | Joshua T. BrummChief Executive Officer, Director | Sell10b5-1 plan | -1,610 | $17.90 | $29 K | 279,602 | Form 4 |
| filed | Barbara Harlin BisphamSee Remarks | Sell10b5-1 plan | -620 | $17.90 | $11 K | 18,710 | Form 4 |
| filed | Ellie Eunkyung ImChief Medical Officer | Sell10b5-1 plan | -623 | $17.90 | $11 K | 21,446 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Crescent Biopharma, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-100 reverse split ; 1-for-3.33 reverse split in the period to
Trading halts
- 2025-06-13 23:50 UTC, code D, resumed 04:00 UTC
Fails to deliver
- : 212 shares at $0.16
- : 4,202 shares at $0.17
- : 18,127 shares at $0.17
- : 162,572 shares at $0.18
- : 360,858 shares at $0.19
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Crescent Biopharma, Inc. scorecard#
Passes 1 of the 6 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$154 M-$154 M in fiscal 2025 against -$51 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$154 MNet income -$154 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-164.2%-164.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities6.6×Current ratio 6.56 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Crescent Biopharma, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 11—100% | — | 0.0−86.7%100% | 0.1−93.5%100% | 1.2−88.6%100% | 10—100% | — | — | — | 0.0—100% | |
| Research and development | 138+868%1273% | 14−29.0%— | 20−29.3%200717% | 28−40.2%37855% | 47+5.7%4095% | 45−4.5%442% | 47+17.3%— | 40+66.4%— | 24+3.5%— | 23—125848% | |
| General and administrative | 25+39.1%234% | 18−5.0%— | 19+0.7%192136% | 19+11.5%25450% | 17+2.2%1476% | 17+16.6%165% | 14+25.8%— | 11+16.1%— | 9.8+13.7%— | 8.7—46758% | |
| Operating expenses | 163+308%1508% | 40+1.9%— | 39−17.3%392853% | 47−26.5%63304% | 65+4.8%5571% | 62+0.5%607% | 61+19.2%— | 52+51.8%— | 34+6.3%— | 32—172605% | |
| Operating income | −153—−1408% | −40—— | −39—−392753% | −47—−63204% | −63—−5471% | −52—−507% | −61—— | −52—— | −34—— | −32—−172505% | |
| Interest expense and finance costs | 2.2—20.1% | — | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | — | 2.2−9.1%— | 2.4—23759% | — | — | — | — | — | 0.7+528%— | 0.1—560% | |
| Income before tax | −152—−1401% | — | — | — | — | — | — | — | — | — | |
| Income tax | 2.0—18.4% | — | — | — | — | — | — | — | — | — | |
| Net income including minority interests | — | −38—— | −37—−368994% | −47—−62252% | −63—−5469% | −51—−502% | −58—— | −48—— | −33—— | −32—−171945% | |
| Net income attributable to shareholders | −154—−1420% | −38—— | −37—−368994% | −47—−62252% | −63—−5469% | −51—−502% | −58—— | −48—— | −33—— | −32—−171945% | |
| Earnings per share, basic | — | -0.59—— | -0.58—— | -0.89—— | -1.23—— | -1.12—— | -1.34—— | -1.18—— | -1.13—— | -1.50—— | |
| Earnings per share, diluted | — | -0.59—— | -0.58—— | -0.89—— | -1.23—— | -1.12—— | -1.34—— | -1.18—— | -1.13—— | -1.50—— | |
| Shares, weighted average (basic) | — | 64+1.8%— | 63+20.6%— | 53+2.1%— | 51+12.5%— | 46+5.7%— | 43—— | — | — | — | |
| Shares, weighted average (diluted) | — | 64+1.8%— | 63+20.6%— | 53+2.1%— | 51+12.5%— | 46+5.7%— | 43+5.4%— | 41+39.6%— | 29+38.3%— | 21—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 213+513%88.7% | 35r11−16.8%97.6% | 42−12.7%92.2% | 48−47.0%92.4% | 90−34.1%95.7% | 137−13.4%95.9% | 158−24.6%94.2% | 210+69.4%97.7% | 124+209%96.4% | 40—94.5% | |
| Receivables | 18—7.5% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Other current assets | 5.5+14276%2.3% | 0.0r0.4−98.1%0.1% | 2.0−29.8%4.4% | 2.8+433%5.5% | 0.5−56.9%0.6% | 1.2−71.4%0.9% | 4.3+84.0%2.6% | 2.4−28.6%1.1% | 3.3+589%2.6% | 0.5—1.1% | |
| Current assets | 237+580%98.5% | 35r11−20.5%97.7% | 44−13.7%96.6% | 51−44.1%97.9% | 91−34.3%96.2% | 138−14.9%96.8% | 163−23.4%96.8% | 212+66.9%98.8% | 127+214%98.9% | 41—95.6% | |
| Property, plant and equipment | 0.8—0.4% | 0—0.0% | — | 0.2−34.3%0.5% | 0.4−40.6%0.4% | 0.6−24.6%0.4% | 0.8−14.0%0.5% | 1.0−13.5%0.4% | 1.1+4.8%0.9% | 1.1—2.5% | |
| Right-of-use (leased) assets | 1.5—0.6% | 0−100%0.0% | 0.8+2.2%1.7% | 0.8−52.3%1.4% | 1.6−32.2%1.7% | 2.3−22.6%1.6% | 3.0—1.8% | — | — | — | |
| Total assets | 240+575%100% | 36r11−21.4%100% | 45−12.5%100% | 52−45.1%100% | 94−33.9%100% | 143−15.0%100% | 168−21.8%100% | 215+67.1%100% | 129+203%100% | 42—100% | |
| Accounts payable | — | 0.3−62.1%0.9% | 0.9−10.5%1.9% | 1.0−54.0%1.9% | 2.1+0.8%2.2% | 2.1+45.6%1.5% | 1.4−46.1%0.9% | 2.7+0.6%1.2% | 2.6+69.1%2.1% | 1.6—3.7% | |
| Current liabilities | 36+275%15.0% | 9.6r5.8+40.7%27.0% | 6.8−23.0%15.1% | 8.9−24.9%17.1% | 12−4.9%12.5% | 12+13.5%8.7% | 11+25.0%6.5% | 8.8+7.2%4.1% | 8.2+29.1%6.4% | 6.3—14.9% | |
| Lease liabilities (non-current) | 1.2—0.5% | 0−100%0.0% | 0.1—0.1% | — | 0.9−52.2%1.0% | 1.9−31.9%1.3% | 2.8—1.7% | — | — | — | |
| Total liabilities | 37−20.8%15.5% | 47r5.8+582%132% | 6.9−22.3%15.2% | 8.9−30.3%17.1% | 13−12.8%13.5% | 15+6.1%10.2% | 14+46.9%8.2% | 9.4+5.6%4.4% | 8.9+25.3%6.9% | 7.1—16.7% | |
| Retained earnings | −172—−71.5% | −18r−494—−50.2% | −456—−1007% | −420—−810% | −373—−395% | −309—−217% | −258—−154% | −201—−93.3% | −152—−118% | −119—−281% | |
| Shareholders' equity | 203—84.5% | −15r5.3−140%−43.5% | 38−10.5%84.8% | 43−47.4%82.9% | 82−36.4%86.5% | 128−16.8%89.8% | 154−25.0%91.8% | 205+71.6%95.6% | 120+239%93.1% | 35—83.3% | |
| Total liabilities and equity | 240+575%100% | 36r11−21.4%100% | 45−12.5%100% | 52−45.1%100% | 94−33.9%100% | 143−15.0%100% | 168−21.8%100% | 215+67.1%100% | 129+203%100% | 42—100% | |
| Shares outstanding | 28+2605%— | 1.0r64−98.4%— | 64+18.4%— | 54+3.9%— | 52r52+6.7%— | 49+12.8%— | 43+0.7%— | 43+25.6%— | 34+47.8%— | 23—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 13+183%123% | 4.7+33.3%— | 3.5−8.6%35245% | 3.9−36.6%5143% | 6.1−11.8%525% | 6.9+11.0%67.9% | 6.2+35.5%— | 4.6+22.0%— | 3.8+26.8%— | 3.0—16026% | |
| Cash from operating activities | −72—−660% | −31—— | −35—−348799% | −46—−61943% | −57—−4957% | −39—−386% | −52—— | −43—— | −30—— | −30—−160710% | |
| Capital expenditure | −0.9—−8.5% | −0.0—— | −0.0—−214% | −0.1—−112% | −0.0—−1.3% | −0.1—−0.7% | −0.1—— | −0.1—— | −0.3—— | −0.7—−3806% | |
| Intangible assets bought | −72—−664% | — | — | — | — | — | — | — | — | — | |
| Cash from investing activities | −73−364185%−672% | 0.0—— | −0.0—−214% | −0.1—−112% | −0.0—−1.3% | −0.1—−0.7% | −0.1—— | −0.1—— | −0.3—— | −0.7—−3806% | |
| Shares issued | 0—0.0% | — | 29+591%287070% | 4.2−61.1%5543% | 11−40.0%923% | 18—175% | — | 128+13.1%— | 114+381%— | 24—127578% | |
| Cash from financing activities | 323+5983301%2978% | 0.0−100.0%— | 29+593%288235% | 4.2−61.2%5543% | 11−40.9%925% | 18+4294%179% | 0.4−99.7%— | 129+13.6%— | 114+381%— | 24—127971% | |
| Change in cash | 179—1646% | −31—— | −6.1—−60778% | −42—−56512% | −47—−4034% | −21—−208% | −52−160%— | 86+2.5%— | 84—— | −6.8—−36546% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 15—100% | 3.1—100% | 0—— | 1.0—100% | 11*—100% | 0—— | 0—— | 0—— | — | — | — | — | — | |
| Research and development | 167+285%1111% | 34+68.6%1101% | 19+60.5%— | 18+68.5%1723% | 95*+40647%876% | 20+1086%— | 12+92.2%— | 11r0.0+76.4%— | 0.2*−95.6%— | 1.7—— | 6.3—— | 6.0—— | 5.3*—— | |
| General and administrative | 33+40.9%218% | 8.7+57.4%280% | 8.7−2.3%— | 7.9+119%757% | 7.3*+43.8%67.4% | 5.5+38.2%— | 8.9+120%— | 3.6r2.4−29.3%— | 5.1*+17.8%— | 4.0—— | 4.1—— | 5.1—— | 4.3*—— | |
| Operating expenses | 199+191%1328% | 43+66.2%1380% | 28+33.8%— | 26+81.2%2480% | 102*+1296%944% | 26+130%— | 21+103%— | 14r2.4+28.0%— | 7.3*−23.6%— | 11—— | 10—— | 11—— | 9.6*—— | |
| Operating income | −182—−1217% | −40—−1280% | −26—— | −25—−2380% | −91*—−844% | −26—— | −21—— | −14r−2.4—— | −7.3*—— | −11—— | −10—— | −11—— | −9.6*—— | |
| Interest expense and finance costs | 0—0.0% | 0—0.0% | 0−100%— | 0−100%0.0% | 0*—0.0% | 0—— | 1.1—— | 1.1—— | — | — | — | — | — | |
| Other non-operating income (expense) | — | 2.2+70.7%70.0% | 1.5—— | 1.4—139% | — | 1.3−9.3%— | −0.8—— | −0.9—— | 0.1*−78.5%— | 1.4—— | — | — | 0.5*—— | |
| Income tax | 2.0—13.3% | 0—0.0% | 0—— | 0—0.0% | 2.0*—18.4% | 0—— | 0—— | 0—— | — | — | — | — | — | |
| Net income including minority interests | — | — | — | — | — | — | — | −2.3—— | −7.2*—— | −9.8*—— | −10*—— | −11—— | −9.1*—— | |
| Net income attributable to shareholders | −109—−728% | −38—−1210% | −25—— | −23—−2241% | −23—−215% | −25—— | −22—— | −15r−2.3—— | −7.2*—— | −9.8—— | −10—— | −11—— | −9.1*—— | |
| Earnings per share, basic | — | — | — | — | — | — | — | -0.04—— | — | -0.15—— | -0.16—— | -0.17—— | — | |
| Earnings per share, diluted | — | — | — | — | — | — | — | — | — | -0.15—— | -0.16—— | -0.04r-0.17—— | — | |
| Shares, weighted average (basic) | — | — | — | — | — | — | — | 65+0.1%— | — | 64—— | 64—— | 64—— | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | — | — | — | — | 64—— | 64—— | 65r64—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 289—96.6% | 289+117%96.6% | 172+12.4%93.9% | 189+743%95.0% | 213+513%88.7% | 133+826%96.4% | 153+582%97.0% | 22r5.6−28.3%374% | 35r11−16.8%97.6% | 14—91.7% | 22—91.7% | 31—91.5% | 42—92.2% | |
| Receivables | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 18—7.5% | — | — | — | 0—0.0% | — | — | — | — | |
| Other current assets | 5.9—2.0% | 5.9+351%2.0% | 7.4+369%4.1% | 6.4+1593%3.2% | 5.5+14276%2.3% | 1.3+3.5%0.9% | 1.6+7.5%1.0% | 0.4−81.0%6.3% | 0.0r0.4−98.1%0.1% | 1.3—8.0% | 1.5—6.0% | 2.0—5.8% | 2.0—4.4% | |
| Current assets | 295—98.6% | 295+119%98.6% | 179+16.1%97.9% | 196+3164%98.2% | 237+580%98.5% | 135+760%97.3% | 154+546%98.0% | 6.0−82.0%100% | 35r11−20.5%97.7% | 16—99.7% | 24—97.7% | 33—97.3% | 44—96.6% | |
| Property, plant and equipment | 0.8—0.3% | 0.8+3.5%0.3% | 0.9+354%0.5% | 0.9—0.5% | 0.8—0.4% | 0.8—0.6% | 0.2—0.1% | — | 0—0.0% | — | — | — | — | |
| Right-of-use (leased) assets | 2.3—0.8% | 2.3+45.8%0.8% | 1.3−20.9%0.7% | 1.4—0.7% | 1.5—0.6% | 1.6—1.1% | 1.6+279%1.0% | — | 0−100%0.0% | — | 0.4—1.7% | 0.6—1.7% | 0.8—1.7% | |
| Total assets | 300—100% | 300+117%100% | 183+16.1%100% | 199+3223%100% | 240+575%100% | 138+781%100% | 157+545%100% | 6.0−82.5%100% | 36r11−21.4%100% | 16—100% | 24—100% | 34—100% | 45—100% | |
| Accounts payable | — | — | — | — | — | — | — | 0.1−86.1%1.7% | 0.3−62.1%0.9% | 0.6—3.7% | 1.0—3.9% | 0.8—2.2% | 0.9—1.9% | |
| Current liabilities | 23—7.8% | 23+15.7%7.8% | 19+10.7%10.1% | 14+442%7.1% | 36+275%15.0% | 20+370%14.7% | 17+284%10.6% | 2.6−50.6%43.7% | 9.6r5.8+40.7%27.0% | 4.3—27.5% | 4.4—17.8% | 5.3—15.5% | 6.8—15.1% | |
| Lease liabilities (non-current) | 1.7—0.6% | 1.7+31.0%0.6% | 1.0−32.6%0.5% | 1.1—0.5% | 1.2—0.5% | 1.3—1.0% | 1.4—0.9% | — | 0−100%0.0% | — | — | — | 0.1—0.1% | |
| Total liabilities | 25—8.4% | 25+16.6%8.4% | 20+7.3%10.7% | 15+484%7.7% | 37−20.8%15.5% | 22+400%15.6% | 18+317%11.5% | 2.6−50.6%43.7% | 47r5.8+582%132% | 4.3—27.5% | 4.4—17.8% | 5.3—15.5% | 6.9—15.2% | |
| Retained earnings | −258—−86.0% | −258—−86.0% | −220—−120% | −195—−98.0% | −172—−71.5% | −79—−57.4% | −55—−34.8% | −497—−8289% | −18r−494—−50.2% | −487—−3103% | −477—−1955% | −467—−1366% | −456—−1007% | |
| Shareholders' equity | 274—91.6% | 274+135%91.6% | 163+17.2%89.3% | 184—92.3% | 203—84.5% | 117—84.4% | 139+594%88.5% | −30r3.4−204%−503% | −15r5.3−140%−43.5% | −1.3r11—−8.3% | 20—82.2% | 29—84.5% | 38—84.8% | |
| Total liabilities and equity | 300—100% | 300+117%100% | 183+16.1%100% | 199+3223%100% | 240+575%100% | 138+781%100% | 157+545%100% | 6.0−82.5%100% | 36r11−21.4%100% | 16—100% | 24—100% | 34—100% | 45—100% | |
| Shares outstanding | 38—— | 38+175%— | 28+99.8%— | 28−57.3%— | 28+2605%— | 14−78.5%— | 14−78.5%— | 65+0.1%— | 1.0r64−98.4%— | 64—— | 64—— | 64—— | 64—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 17+75.4%114% | 4.2+113%135% | 4.0−25.7%— | 4.1+235%396% | 4.7*+309%43.8% | 2.0+74.4%— | 5.3+342%— | 1.2r0.4+3.1%— | 1.2*+27.7%— | 1.1—— | 1.2—— | 1.2—— | 0.9*—— | |
| Cash from operating activities | −82—−547% | −27*—−864% | −19*—— | −8.9—−860% | −27*—−247% | −18*—— | −16r−22*—— | −11r−5.1—— | −3.7*—— | −8.0*—— | −8.9*—— | −11—— | −7.6*—— | |
| Capital expenditure | −0.4—−2.4% | 0*—0.0% | −0.0*—— | −0.1—−14.1% | −0.2*—−1.8% | −0.6*—— | −0.1*—— | 0—— | 0*—— | 0*—— | −0.0*—— | −0.0—— | −0.0*—— | |
| Intangible assets bought | −80—−533% | 0*—0.0% | 0*—— | −8.0—−770% | −72*—−664% | 0*—— | 0*—— | 0—— | — | — | — | — | — | |
| Cash from investing activities | −79—−524% | 0*—0.0% | 1.8*—— | −8.1—−784% | −72*−240743%−666% | −0.6*—— | −0.1*—— | 0—— | 0.0*—— | 0*—— | −0.0*—— | −0.0—— | −0.0*—— | |
| Shares issued | — | — | — | — | 0*—0.0% | — | — | — | — | — | — | — | 0*—— | |
| Cash from financing activities | 317+120%2112% | 145*—4646% | 0.1*−99.9%— | −6.9—−668% | 179*—1649% | −1.3*—— | 147*+29372700%— | −1.5−30439%— | 0*−100%— | 0*—— | 0.0*—— | 0.0—— | 0.0*—— | |
| Change in cash | 156+64.5%1041% | 118*—3782% | −18*−113%— | −24—−2313% | 80*—737% | −19*—— | 130r123*—— | −12r−5.1—— | −3.7*—— | −8.0*—— | −8.9*—— | −11—— | −7.6*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Crescent Biopharma, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable$11 M100%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Crescent Biopharma, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Joshua Brumm | $13.1 M | $17.6 M | $5.1 M | $4 |
| 2024(1)Harout Semerjian | $2.9 M | $16 K | $1.4 M | $8 |
| 2023(1)Harout Semerjian | $2.4 M | $1.7 M | $1.2 M | $78 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Crescent Biopharma, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 2 · Auditor changed 1 · Restructuring 1 · Change in control 2 · Acquisition or sale completed 1 · Directors and officers 7 · Material agreement 5 · Agreement ended 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Auditor changedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changedResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Directors and officersAgreement ended | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Change in controlDirectors and officersMaterial agreementUnregistered share sale | 8-K | |
| RestructuringDirectors and officers | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | 26 | · | · | · | · | · | 26 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 26 people (80% of workforce) | Restructuring planSEC 8-K | “In connection with the streamlined operating plan approved by the Board, on July 24, 2024, the authorized officers of the Company committed the Company to a corporate restructuring…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Crescent Biopharma, Inc. compares in Biotechnology
- Revenue$11 M · higher than 44% of 647
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Crescent Biopharma, Inc.🇺🇸 | $195 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Crescent Biopharma, Inc.? Verify and update this profile — free
Show Crescent Biopharma, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.